Compare Amphastar Pharmaceuticals Inc (AMPH) vs Hasbro, Inc. (HAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Hasbro, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Hasbro, Inc. trades at $80 (market cap $11.17B). The key difference: Hasbro, Inc. is far larger — about 13.5× Amphastar Pharmaceuticals Inc's market cap, and Hasbro, Inc. pays a 3.55% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | HAS | |
|---|---|---|
Market Cap | $826.08M | $11.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $105.88 |
52-Week Low | $16.87 | $70.95 |
Enterprise Value | $1.22B | $13.44B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Hasbro (HAS) trades at $78.96, up 2.03% today, with a bearish technical signal but bullish oscillators suggesting potential reversal. The company reported negative net income of -$322.4M in 2025 despite revenue growth to $4.7B. Recent earnings beats and a $0.70 dividend highlight operational resilience, while analyst consensus targets $104.80. News highlights include new product launches like Blooms by Play-Doh and strong performance in the Wizards segment.
Outlook: Upside exists from analyst targets and earnings momentum, but risks include high debt, margin pressure, and competitive threats. The stock presents a contrarian opportunity if operational improvements continue, though volatility near key support at $76 warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
